Intravitreal ranibizumab for macular edema secondary to retinal vein occlusion. (Q53392620)

13 May 2018

title

Intravitreal ranibizumab for macular edema secondary to retinal vein occlusion. (English)

1 reference

13 May 2018

author name string

Moosang Kim

1

1 reference

13 May 2018

Seung-Young Yu

2

1 reference

13 May 2018

Eung-Suk Kim

3

1 reference

13 May 2018

So Hyun Bae

4

1 reference

13 May 2018

Jung Hyun Park

5

1 reference

13 May 2018

Hyeong Gon Yu

6

1 reference

13 May 2018

Hyung-Woo Kwak

7

1 reference

13 May 2018

publication date

29 December 2011

1 reference

13 May 2018

published in

Ophthalmologica

1 reference

13 May 2018

volume

227

1 reference

13 May 2018

issue

3

1 reference

13 May 2018

page(s)

132-138

1 reference

13 May 2018

The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia

cites work

1 reference

Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema

21 January 2018

1 reference

Intravitreal triamcinolone acetonide for treatment of serous macular detachment in central retinal vein occlusion

21 January 2018

1 reference

One-year safety and efficacy of intravitreal triamcinolone acetonide for the management of macular edema secondary to central retinal vein occlusion

21 January 2018

1 reference

Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders

21 January 2018

1 reference

Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial

21 January 2018

1 reference

The effects of intravitreal bevacizumab on patients with macular edema secondary to branch retinal vein occlusion

21 January 2018

1 reference

Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study

21 January 2018

1 reference

Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study

21 January 2018

1 reference

Clinical practice. Retinal-vein occlusion

21 January 2018

1 reference

One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion

21 January 2018

1 reference

Efficacy and safety of anti-vascular endothelial growth factor (VEGF) therapy with intravitreal ranibizumab (Lucentis) for naive retinal vein occlusion: 1-year follow-up.

21 January 2018

1 reference

Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion

21 January 2018

1 reference

Association between integrity of foveal photoreceptor layer and visual acuity in branch retinal vein occlusion

21 January 2018

1 reference

Foveal photoreceptor layer in eyes with persistent cystoid macular edema associated with branch retinal vein occlusion

21 January 2018

1 reference

Integrity of foveal photoreceptor layer in central retinal vein occlusion

21 January 2018

1 reference

Evaluation of potential visual acuity in eyes with macular oedema secondary to retinal vein occlusion.

21 January 2018

1 reference

Predictive factors for changes in macular edema in intravitreal bevacizumab therapy of retinal vein occlusion

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1159/000334906

1 reference

13 May 2018

1 reference

13 May 2018